A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 19 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Dec 2016 Results of long term immunogenecity of elosulfase alfa published in the Clinical Therapeutics.
- 20 Oct 2016 This trial was completed in Germany (end date: 2016-06-16), according to European Clinical Trials Database.